Decibel Therapeutics (NSDQ:DBTX) has a working hypothesis that molecular characterization of the cell biology of the inner ear could pave the way for treatments for hearing and balance disorders.  The Boston-based biotech company has announced that a recent study published in Cell Reports supports that hypothesis.  “We were thrilled to leverage our data and expertise in inner…